The Prevalence and Determinants of Anaemia among Clients of the AIDS Support Organisation-Entebbe, Uganda

Download Article

DOI: 10.21522/TIJPH.2013.09.04.Art022

Authors : Edward Kibikyo Mukooza, Lydia Nakyeyune, Henry Sseguya, Ekiria Kikule


Anaemia, a common hematological disorder in HIV infection, compromises the quality of life and treatment outcomes. At The AIDS Support Organisation (TASO), Entebbe, the records for the 2016-2018 period show a 10% prevalence of anaemia which is lower than that in literature where it is said to be up to 95%. This study determined the prevalence, type, severity, and determinants of anaemia among people living with HIV and AIDS who receive care from TASO Entebbe in Uganda. A questionnaire was used to collect data from 624 TASO clients. A checklist identified the clients’ Antiretroviral Therapy (ART) combination and viral load. The selected clients’ Body Mass Index (BMI) was calculated to assess their nutritional status. A Fully Automated Humacount 60TS Three-Part Hematology Analyzer was used to measure hemoglobin and to do a full blood count. A blood film from each sample was manually examined for the type of anaemia. Data analysis was done with Stata MP 15. The prevalence of anaemia was 44.4%, and the anaemia was mostly mild (54.15%) to moderate (40.80%). Anaemia of inflammation was the commonest type (>58%). Gender, viral suppression, nutritional status, nutritional education, marital and economic status were significantly associated with the anaemia. Duration on ART had a protective effect, but this was not statistically significant. The prevalence of anaemia (44.4%) among the TASO-Entebbe Uganda clients was high, but the anaemia was mostly mild to moderate (>94%) and of inflammation type (>58%). Management of anaemia in HIV requires intentional screening since it compromises treatment outcomes.

Keywords: Prevalence of anaemia in HIV, Determinants of anaemia in HIV, Uganda, TASO.


[1] WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO/NMH/NHD/MNM/11.1. 2011a.

[2] WHO. Worldwide prevalence of anaemia 1993–2005 WHO Global Database on Anaemia. 2008.;jsessionid=D8A6BB532C215E958051A421AE7CE613?sequence=1.

[3] Kassebaum NJ. The Global Burden of anaemia. 2013.

[4] WHO. Anaemia. 2020a.

[5] Chaparro, CM., & Suchdev, PS. anaemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Annals of the New York Academy of Sciences, 1450(1), 15–31. 2019.

[6] Enawgaw B, Alem M, Melku M, et al., Prevalence and associated risk factors of anaemia among HIV infected children attending Gondar university hospital, Northwest Ethiopia: a cross sectional study. BMC hematology, 15, 12. 2015.

[7] UNAIDS. Global HIV Statistics. 2019a.

[8] UNAIDS. Uganda AIDS Country Progress Report July 2017-June 2018. 2019b.

[9] Belperio PS and Rhew DC. Prevalence and outcomes of anaemia in individuals with human immunodeficiency virus: a Systematic Review of the Literature. 2004 Am J Med 116(Suppl7A):27S–43S. CrossRef Medline Google Scholar.

[10] Johannessen A, Naman E, Gundersen SG. et al. Antiretroviral treatment reverses HIV-associated anaemia in rural Tanzania. BMC Infect Dis 11, 190 (2011).

[11] [11] Melese H, Wassie MM, Woldie H, et al., anaemia among adult HIV patients in Ethiopia: a hospital-based Cross-sectional study. HIV/AIDS (Auckland, N.Z.), 9, 25–30. 2017

[12]  World Health Organization. Strategies to Prevent anaemia, recommendation from an expert group consultation. 2015. 20 Avenue Appia, 1211 Geneva 27, Switzerland.

[13] FAO. Nutritional Status Assessment and Analysis Nutritional Status Indicators Learner Notes. 2007.

[14] DeMaeyer EM, Dallman P, Gurney JM, et al., World Health Organization. Preventing and Controlling Iron Deficiency Anaemia Through Primary Health Care. A guide for Health Administrators and Program Managers. 1989‎. (accessed on 25th September 2020).

[15] WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization. 2011b. (WHO/NMH/NHD/MNM/11.1) pdf, accessed [19th September 2020].

[16] GOV.UG. Uganda at a glance; Facts and Figures. n.d.

[17] Lokpo SY, Ofori-Attah P, Ameke LS, et al., “Viral Suppression and Its Associated Factors in HIV Patients on Highly Active Antiretroviral Therapy (HAART): A Retrospective Study in the Ho Municipality, Ghana”, AIDS Research and Treatment, vol. 2020, Article ID 9247451, 7 pages, 2020.

[18] McMahon JH, Elliott JH, Bertagnolio S, et al., Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bulletin of the World Health Organization, 91(5), 377–385E. 2013.

[19] Nalugoda F, Guwatudde D, Bwaninka JB, Makumbi FE, Lutalo T, Kagaayi J, Sewankambo NK, Kigozi G, Serwadda DM, Kong X, Wawer MJ, Wabwire-Mangen F, & Gray RH. (2014). Marriage and the risk of incident HIV infection in Rakai, Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 65(1), 91–98.

[20] Walque, DD, & Kline R. The association between remarriage and HIV infection in 13 sub-Saharan African countries. Studies in family planning, 43 1, 1-10. 2012.

[21] UBOS. Statistical Abstract. 2018.

[22] The World Bank. Literacy rate, adult total (% of people ages 15 and above). From: 2020. Accessed on the 26th of May 2020.

[23] WHO. Global status report on alcohol and health. 2018a.

[24] MOH. Global adult tobacco survey: country report 2013. 2013.

[25] UBOS. Demographic and Health Survey. 2016.

[26] Kyeyune R, Saathoff E, Ezeamama AE. et al. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect Dis 14, 496. 2014.

[27] Mugisha JO, Shafer LA, Van der Paal L, et al., Aneamia in a rural Ugandan HIV cohort: prevalence at enrolment, incidence, diagnosis, and associated factors. Medical Research Council (MRC/UVRI) Uganda Research Unit on AIDS, Entebbe, Uganda. 2008.

[28] Denue BA, Kida IM., Hammagabdo A, et al., Prevalence of anaemia and Immunological Markers in HIV-Infected Patients on Highly Active Antiretroviral Therapy in North-eastern Nigeria. Infectious diseases, 6, 25–33. 2013.

[29] Owiredu WKBA, Quaye L, Amidu N, Addai-Mensah O. Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART. Afr Health Sci. 2011;11(1):2–15.

[30] Tamir Z, Alemu J, & Tsegaye A. anaemia among HIV Infected Individuals Taking ART with and without Zidovudine at Addis Ababa, Ethiopia. Ethiopian journal of health sciences, 28(1), 73–82. 2018.

[31] Volberding PA, Levine AM, Dieterich D, et al., Clinical Impact and Evidence-Based Management Strategies, Clinical Infectious Diseases, Volume 38, Issue 10, 15 May 2004, Pages 1454–1463, 2004.

[32] Gebremedhin KB and Haye TB. 2019. Factors Associated with anaemia among People Living with HIV/AIDS Taking ART in Ethiopia. 2019.

[33] Lundgren JD and Mocroft A. anaemia and Survival in Human Immunodeficiency Virus. Clinical Infectious Diseases 37(Suppl 4): S297–303 2003.

[34] Maskew M, Brennan AT, Sanne I, et al., 2013. anaemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement in Hemoglobin regardless of Degree of Immunosuppression and the Initiating ART Regimen. From:

[35] Woldeamanuel GG, Wondimu DH. Prevalence of anaemia before and after initiation of antiretroviral therapy among HIV infected patients at Black Lion Specialized Hospital, Addis Ababa, Ethiopia: a cross sectional study. BMC Hematol 18, 7. 2018.

[36] Weiss G, Ganz T and Goodnough LT. 2019. anaemia of inflammation: Iron Metabolism and Its Disorders| January 3, 2019. From:

[37] Ganz. T. Molecular pathogenesis of anaemia of chronic disease. 2005.

[38] Makubi A, Okuma J, Spiegelman D, et al., Burden and Determinants of Severe anaemia among HIV-Infected Adults: Results from a Large Urban HIV Program in Tanzania, East Africa. 2013.

[39] Jaganath D, Walker AS, Ssali F, et al., DART Trial, & ARROW Trial. HIV-associated anaemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. AIDS research and human retroviruses, 30(6), 523–530. 2014.

[40] Sbarra DA. (2015). Divorce and health: current trends and future directions. Psychosomatic medicine, 77(3), 227–236.

[41] NIH. 10 Things to Know About HIV Suppression. 2020.

[42] May MT, Gompels M, Delpech V, et al., UK Collaborative HIV Cohort (UK CHIC) Study. Impact on the life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (London, England), 28(8), 1193–1202. 2014

[43] WHO. 2018b. Viral suppression for HIV treatment success and prevention of sexual transmission of HIV. From:

[44] Bailey KV1 & Ferro-Luzzi A. Use of body mass index of adults in assessing individual and community nutritional status. 1995.

[45] WHO. 2020b. Body mass index – BMI. From:

[46] WHO. Malnutrition. 2020c.

[47] Semba RD, Shah N, Klein RS, et al.,, Human Immunodeficiency Virus Epidemiology Research Study Group, Prevalence and Cumulative Incidence of and Risk Factors for anaemia in a Multi-center Cohort Study of Human Immunodeficiency Virus–Infected and –Uninfected Women, Clinical Infectious Diseases, Volume 34, Issue 2, 15 January 2002, Pages 260–266,

[48] Richard MD and Darrell F. Anaemia in HIV-infected patients receiving highly active antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999), 29(1), 54–57. 2002.

[49] Yesuf T, Muhie OA, Shibru H. Prevalence and predictors of anaemia among adult HIV infected patients at the University of Gondar Hospital, Northwest Ethiopia. HIV AIDS (Auckl). 2019; 11:211-217

[50] WHO. 2000. Obesity: preventing and managing the global epidemic Report of a WHO Consultation (WHO Technical Report Series 894).